dearest cato
good point. they played the strategy at the time in anticipation for agvhd approval, and possibly even the ards covid treatment potentially getting a green light - no point getting approval for the largest disease sweeping the world when you dont have the PPE in place to produce enough for everyone. as we know msb got shafted on agvhd, and ards treatment is anyones guess now. they made the best decision they could at the time and it didnt pan out. the price lost many dollars to the share price. "mistakes" made but we move forward.
But not all is lost, in fact it looks like all uncertainty surrounding the balance sheet will be put aside for at least a year with a big investor coming in. targeted INDUSTRY investor - someone smarter and with more resources than anyone on this forum, including the very clever Cato - likely to finance further trial in adults - assuming all goes well, this will likely get an eventual approval for the children (assuming no accelerated approval short term) and the adults.
CHF trials looked amazing (might even be getting funds for further trial on this, but with mortality being the gold standard for the FDA and 60% reduction, accelerated approval is possibly right around the corner) and back pain data looked fine i'm sure grunenthal will be happy to pay them for a milestone or two going forward.
The Novartis might walk narrative i still don't buy it - seems to be something that spawned on HC forums from some initial low info down rampers and people have just ran with it. Novartis have signed up for all cause ards for starters, and im sure Novartis are smarter than to enter an agreement publicly no more than a few weeks before the 60% hurdle is announced? they still haven't seen the un-blinded data yet, and i do have a hunch that while the 45% target for improved mortality wasn't reached, based on the original 12 patients (83%, 75% discharged from hospital at the time) and hitting the first two hurdles (30% and 45% ?), wont be surprised if they think its the goods.
If you don't have confidence in the company in the above that's fine, don't buy. also, IMO you really need to get over the fact that ecoool was a highly revered, well informed, well written eloquent poster who was revered moreso than yourself, and we all know who was partially responsible for what seems to be his indefinite absence....
- Forums
- ASX - By Stock
- MSB
- Ann: Half Year Report and Accounts (including Appendix 4D)
Ann: Half Year Report and Accounts (including Appendix 4D), page-247
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B |
Open | High | Low | Value | Volume |
$1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 24758 | $1.49 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.49 | 73626 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10033 | 1.485 |
4 | 53700 | 1.480 |
1 | 770 | 1.475 |
3 | 62048 | 1.460 |
1 | 50000 | 1.455 |
Price($) | Vol. | No. |
---|---|---|
1.490 | 21995 | 1 |
1.505 | 24000 | 1 |
1.510 | 13666 | 2 |
1.515 | 99798 | 1 |
1.520 | 27250 | 3 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |